Hi folks! Let me know your thoughts on the video, or anything else 😀 One other question I had, but couldn't fit into the presentation about this information was: What is the maximum dose of HIV that leronlimab could protect against?
Great job on this! You captured the important scientific findings and presented them in a really accessible manner. In answer to your question, any dose so long as full receptor occupancy is achieved.
Leronlimab has already completed its ph 3 with extremely impressive numbers google Charlie sheen Leronlimab currently cyto is submitted 2 sections of its BLA to the FDA the 3rd and final sec will be submitted 1st quarter next yr. If the FDA approves of the BLA it will give Leronlimab a PDfu date usually 6 months to formal approval, Leronlimab will be known as vyrologix once it’s marketed
@@thomassmith7542 I have seen that Cytodyn had completed its phase 3 and posted the results on their website, and that they are waiting on approval of its BLA that it is submitting in parts. I was referring to the journal article that usually accompanies these phase 3 results (which is usually delayed in publishing), because I am looking forward to presenting on that 😁
The latest information that I could find on lenacapavir is that it has been submitted for a new drug administration in June 2021 and it has phase 2/3 trials that are ongoing. There are also clinical trials that are started where it will have its properties investigated as PrEP. These studies should conclude in 2024
Hi folks! Let me know your thoughts on the video, or anything else 😀
One other question I had, but couldn't fit into the presentation about this information was: What is the maximum dose of HIV that leronlimab could protect against?
Great job on this! You captured the important scientific findings and presented them in a really accessible manner. In answer to your question, any dose so long as full receptor occupancy is achieved.
Hopefully Leronlimab will be approved late next year, it will be a game changer. Leronlimab safety and easy administration makes it a no brainer
Hopefully! I am looking forward to the release of their official trial results too 🙂
This medication looks extremely promising!
Leronlimab has already completed its ph 3 with extremely impressive numbers google Charlie sheen Leronlimab currently cyto is submitted 2 sections of its BLA to the FDA the 3rd and final sec will be submitted 1st quarter next yr. If the FDA approves of the BLA it will give Leronlimab a PDfu date usually 6 months to formal approval, Leronlimab will be known as vyrologix once it’s marketed
@@thomassmith7542 I have seen that Cytodyn had completed its phase 3 and posted the results on their website, and that they are waiting on approval of its BLA that it is submitting in parts.
I was referring to the journal article that usually accompanies these phase 3 results (which is usually delayed in publishing), because I am looking forward to presenting on that 😁
Thank for spreading the word on Leronlimab. I can't wait for the drug to be aproved.
I am excited for it to be approved as well!
I would like to learn more about leronlimab. Thank you
Any information on gilead lenacapavir.... although islatravir is presently on hold...but I believe the former will be a game changer
The latest information that I could find on lenacapavir is that it has been submitted for a new drug administration in June 2021 and it has phase 2/3 trials that are ongoing. There are also clinical trials that are started where it will have its properties investigated as PrEP. These studies should conclude in 2024